1	ORIGINAL ARTICLE			
2				
3	Risk score	s and coronary artery disease in patients with		
4	suspected	l acute coronary syndrome and intermediate		
5		cardiac troponin concentrations		
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Daniel P Dimitrios I Takeshi Fujisawa ¹ BHF/University Centr ² Usher Institute, Univer ³ Edinburgh Heart Centr ⁴ Department of Emerg Edinburgh, Edinburgh, ⁵ Edinburgh Imaging Fa [*] Contributed equally	erez-Vicencio, MSc, ^{1,2*} Alexander JF Thurston, BMBCh, ^{3*} Doudesis, PhD, ^{1,2} Rachel O'Brien, BN, ⁴ Amy V. Ferry, PhD, ¹ A, PhD, ¹ Michelle C. Williams, MBCHB, ^{1,5} Alasdair J. Gray, MD, ^{2,4} Nicholas L Mills, MD, ^{1,2} Kuan Ken Lee, MD ^{1,3} e for Cardiovascular Science, University of Edinburgh, Edinburgh, UK rsity of Edinburgh, Edinburgh, UK re, Royal Infirmary of Edinburgh, Edinburgh, UK gency Medicine, Emergency Medicine Research Group, Royal Infirmary of UK cility, University of Edinburgh, Edinburgh, UK		
25	Corresponding Author:			
26	Dr Kuan Ken Lee			
27 28	BHF/University Centre for Cardiovascular Science			
20	Edinburgh EH16 4SA			
30	United Kingdom			
31	Telephone: 0044 131 242 6515			
32 33 34 35	E-mail: <u>ken.lee@ed.a</u>	<u>c.uk</u>		
36	Abstract:	250		
37	Word count:	4,370		
38	References:	36		
39				

1 Abstract

Background: Guidelines recommend the use of risk scores to select patients for further
investigation after myocardial infarction has been ruled out but their utility to identify those
with coronary artery disease is uncertain.

5 Methods: In a prospective cohort study, patients with intermediate high-sensitivity cardiac

6 troponin I concentrations (5 ng/L to sex-specific 99th percentile) in whom myocardial

7 infarction was ruled out were enrolled and underwent coronary computed tomography

8 angiography (CCTA) after hospital discharge. HEART, EDACS, GRACE, TIMI, SCORE2

9 and PCE risk scores were calculated and the odds ratio (OR) and diagnostic performance for

10 obstructive coronary artery disease determined using established thresholds.

Results: In 167 patients enrolled (64 ± 12 years, 28% female), 29.9% (50/167) had obstructive

12 coronary artery disease. The odds of having obstructive disease was increased for all scores

13 with the lowest and highest increase observed for an EDACS score ≥ 16 (OR 2.2 [1.1-4.6])

and a TIMI risk score ≥ 1 (OR 12.9 [3.0-56.0]), respectively. The positive predictive value

15 (PPV) was low for all scores but was highest for a GRACE score >88 identifying 39% as

16 high-risk for a PPV of 41.9% (30.4-54.2%). The negative predictive value (NPV) varied from

17 77.3% to 95.2% but was highest for a TIMI score of 0 identifying 26% as low-risk for a NPV
18 of 95.2% (87.2-100%).

Conclusions: In patients with intermediate cardiac troponin concentrations in whom
myocardial infarction has been ruled out, clinical risk scores can help identify patients with
and without coronary artery disease, but the performance of established risk thresholds
requires optimisation for this purpose.

23 Clinical Trial Registration: https://clinicaltrials.gov/study/NCT04549805

- 1 Key words: acute coronary syndrome, cardiac troponin, risk scores, CT coronary
- 2 angiography, coronary artery disease

1 Non-standard Abbreviations and Acronyms

- 2 CCTA Coronary Computed Tomography Angiography
- 3 HEART History, Electrocardiogram, Age, Risk factors, and Troponin
- 4 EDACS Emergency Department Assessment of Chest Pain Score
- 5 TIMI Thrombolysis in Myocardial Infarction
- 6 GRACE 2.0 Global Registry of Acute Coronary Events version 2.0
- 7 ASCVD-PCE Atherosclerosis Cardiovascular Disease Pooled Cohort Equations
- 8 SCORE2 Systematic COronary Risk Evaluation 2
- 9 MACE Major Adverse Cardiac Events

1 Introduction

2 Current strategies to assess patients with suspected acute coronary syndrome in the 3 Emergency Department primarily utilise high-sensitivity cardiac troponin testing and the 4 electrocardiogram to rule in and rule out myocardial infarction [1, 2]. Single measurement 5 rule-out pathways are optimised to identify patients with low cardiac troponin concentrations 6 who can be safely discharged from the Emergency Department without further testing and 7 those with elevated concentrations who require admission for further assessment [3-8]. 8 However, 1 in 4 patients have intermediate cardiac troponin concentrations and whilst they 9 can be ruled out or ruled in with a second troponin measurement, they remain at higher risk of future adverse cardiac events [5, 9-11]. Similarly serial testing pathways with cardiac 10 11 troponin measurement at 0/1- and 0/2-hours stratify patients into three groups including an 12 observe zone group with intermediate concentrations [12, 13]. Guidelines recommend further investigation is considered in these patients but the optimal approach to select these patients 13 14 for investigation is unknown [2, 14].

15

16 Clinical risk scores are widely used in the Emergency Department to risk stratify patients 17 with suspected acute coronary syndrome [15-18]. However, the utility of these risk scores is 18 uncertain, particularly following the widespread adoption of high-sensitivity cardiac troponin 19 as a risk stratification tool [19]. Derived from historical cohorts, risk scores may lack external 20 validity when applied to contemporary practice [20], and some include elements of the history or clinician gestalt, that may be subjective or vulnerable to bias. Nevertheless, recent 21 22 guidelines continue to recommend the use of clinical risk scores to select patients with 23 intermediate cardiac troponin concentrations for further testing [1, 2].

- 1 In a secondary analysis of the PRECISE-CTCA study [21], we evaluate the performance of
- 2 clinical risk scores to identify coronary artery disease in patients with intermediate cardiac
- 3 troponin concentrations in whom myocardial infarction has been ruled out.

1 Methods

2 Study design and population

PRECISE-CTCA (Troponin to Risk Stratify Patients with Acute Chest Pain for Computed 3 4 Tomography Coronary Angiography) was a prospective cohort study conducted at the Royal 5 Infirmary of Edinburgh, United Kingdom, between December 4, 2018, and October 6, 2020, 6 that has previously reported (ClinicalTrials.gov, number NCT04549805) [21]. Patients >30 7 years old presenting with suspected acute coronary syndrome, in whom myocardial infarction 8 had been ruled out and peak cardiac troponin concentrations were within the normal 9 reference range, were recruited in the Emergency Department [21]. Patients who were unable to undergo CCTA due to severe renal failure (estimated glomerular filtration rate <30 10 $mL/min/1.73 m^2$) or major allergy to iodinated contrast media, clear alternative diagnosis, 11 12 requirement for in-patient investigation, CCTA or invasive coronary angiogram within the past 1 year, pregnancy or breast feeding and inability to give informed consent were 13 14 excluded. The South East Scotland Research Ethics Committee 01 approved this study, and all participants provided written informed consent. 15

16

Only patients with intermediate cardiac troponin concentrations (between 5 ng/L and the sex-17 specific 99th percentile) were included in this secondary analysis. Cardiac troponin was 18 19 measured using the ARCHITECT_{STAT} high-sensitivity cardiac troponin I assay (Abbott 20 Laboratories, Abbott Park, Illinois). This assay has a limit of detection of 1.2 ng/L and an inter-assay co-efficient of variation of <10% at 4.7 ng/L, with a sex-specific upper reference 21 limit or 99th percentile of 16 ng/L in females and 34 ng/L in males [22]. According to current 22 national and international recommendations, symptoms of angina were classified as typical, 23 24 atypical, or nonanginal chest pain using the Diamond and Forrester questions [23].

1 Coronary Computed Tomography Angiography

2 All participants underwent CCTA as an outpatient as soon as possible after their initial 3 hospital attendance. CCTA was performed using a 128-detector row scanner (Biograph mCT, 4 Siemens Healthcare, Germany) with iodine-based contrast media, as per Society of 5 Cardiovascular Computed Tomography (SCCT) guidelines [24]. All CCTA images were 6 analysed by trained observers who performed a per-segment analysis using a 15-segment 7 model to assess coronary artery stenoses. Luminal cross-sectional area stenoses were 8 classified as normal (<10%), mild non-obstructive (10%-49%), moderate non-obstructive 9 (50%-70%), or obstructive (>70\% in the >1 major epicardial artery or >50\% in the left main 10 stem). Patients were classified according to the most significant stenosis identified on CCTA 11 irrespective of whether the vessel has been stented. Coronary stenoses that were bypassed by 12 a vascular graft were not considered in the classification.

13

14 Clinical risk scores

We calculated the HEART, EDACS, GRACE 2.0, TIMI, PCE, and SCORE2 risk scores in 15 16 all patients and used established thresholds for each to stratify patients as low or high risk 17 (Supplemental Text 1 and Supplemental Figure 1) [17, 25-31]. The HEART score assesses risk of major adverse cardiac events at 6 weeks in patients presenting with chest pain to the 18 Emergency Department using a threshold of <3 to identify those who are low-risk [25]. The 19 20 EDACS score assesses risk of major adverse cardiac events at 30 days in patients presenting 21 with chest pain to the Emergency Department using a threshold of <16 to identify those who 22 are low-risk [17]. The GRACE 2.0 score assesses risk of death or recurrent myocardial 23 infarction at 6 months in patients with acute coronary syndromes identifying patients with a 24 score >88 at increased risk [17]. TIMI score assess the risk of death, re-infarction or ischemic 25 events at 14 days in patients with acute coronary syndrome with as score of ≥ 1 associated

with increased risk [27]. The PCE predicts risk of a first atherosclerotic cardiovascular
disease event at 10 years with the score associated with a <5% selected as low risk [28, 29].
SCORE2 and SCORE2-OP estimates the risk of fatal cardiovascular disease at 10 years in
adults aged 40-69 and 70 years or older, respectively. The SCORE2 and SCORE2-OP risk
scores are used together in this analysis and were calibrated for low-risk regions with the
score associated with a <5% selected as low risk [30, 31] (*Supplemental Text 1*).

7

8 Statistical analysis

9 Baseline characteristics were presented as mean ± standard deviation or median [interquartile range] for continuous variables and as count (%) for categorical variables. The Welch two-10 sample *t*-test test and one-way ANOVA were used to compare continuous variables while 11 12 Fisher's exact test was used to compare categorical variables. Multiple imputation by chained equation or Markov chain Monte Carlo method was performed to account for missing 13 14 variables [32]. We multiple-imputed all missing values in the variables required to calculate clinical risk scores except for cardiac troponin concentrations (Supplemental Figure 2). We 15 16 evaluated the association between the clinical risk scores and presence of any coronary artery 17 disease and obstructive coronary artery disease separately using binomial logistic regression modelling by obtaining the exponential of the logistic regression coefficient. We calculated 18 19 the diagnostic performance for each clinical risk score with 95% confidence intervals of the 20 sensitivity, specificity, negative predictive value, and positive predictive value based on the 21 rule-in/rule-out thresholds. Overall diagnostic accuracy was evaluated by receiver operating 22 characteristic (ROC) curve and area under the curve analyses. All calculations were 23 performed for any coronary artery disease and obstructive disease separately. We subsequently performed a sensitivity analysis restricted to patients who were not previously 24

- 1 known to have coronary artery disease (*Supplemental Table 1*). All data analysis were
- 2 conducted in R (version 4.3.0, R Foundation for Statistical Computing).

1 **Results**

2 Study population

3 In this secondary analysis 167 patients (64±12 years, 28% female) were included with

4 intermediate cardiac troponin I concentrations and a median maximal concentration of 8 ng/L

5 (inter-quartile range 6-12 ng/L). Of these patients, 120 (72%) had coronary artery disease and

6 50 (30%) had obstructive coronary artery disease on CCTA (*Table 1*).

7

8 Patients with coronary artery disease were older than those without (67±10 years versus 9 56±13 years, respectively; P<0.001) and more likely to be current or previous smokers (59% 10 [71/120] versus 38% [18/47]; P=0.017). Patients with coronary artery disease were also more 11 likely to have hypertension (57% [68/120] versus 23% [11/47]; P=0.017), diabetes mellitus 12 (23% [27/120] versus 6.4% (3/47]; P=0.014) and chronic kidney disease (14% [17/120] 13 versus 4.3% [2/47]; P=0.010) compared to those without (Table 1). Similarly, patients with 14 coronary artery disease were also more likely to have symptoms of typical angina (27% [32/120] versus 4.3% [2/47]; P=0.001) and to have both previous myocardial infarction (31% 15 16 [37/120] versus 6.4% [3/47]; P<0.001) and percutaneous coronary intervention (31% [37/120] versus 6.4% [3/47]; P<0.001) than those without (Table 1). Similar findings were 17 observed when stratified according to the presence or absence of obstructive coronary artery 18 19 disease (Supplemental Table 2).

20

21 Distribution of clinical risk scores

The median scores for patients with obstructive disease were significantly higher than those
without coronary artery disease for all risk scores, HEART (5 ([inter-quartile range 4-5] *versus* 3 [2-4.5]; P<0.001), EDACS (18 [14-24] *versus* 14 [10.8-17]; P=0.002), GRACE (88
[77-108] *versus* 62 [45-73]; P<0.001), TIMI (2 [1-3] *versus* 0 [0-1]; P<0.001), PCE (0.32

[0.16-0.45] versus 0.09 [0.04-9]; P<0.001), and SCORE2 (15 ([8.5-18.8] versus 5 [4-9];
 P<0.001), respectively (*Figure 1 & Supplemental Table 2*). Similarly, patients with
 obstructive coronary artery disease had higher median scores than those with non-obstructive
 disease (*Supplemental Table 2*).

5

6 Diagnostic performance of clinical risk scores

7 Patients with risk scores above the established risk threshold were more likely to have 8 coronary artery disease than those below the risk threshold (*Figure 2*). The odds ratio of 9 having any coronary artery disease or obstructive disease was increased for all scores 10 comparing those with increased scores to those with scores below the risk threshold. The 11 odds ratio for obstructive coronary artery disease varied with the lowest increase observed for 12 an EDACS score ≥ 16 (OR 2.2 [1.1-4.6]) and the highest increase for a TIMI risk score ≥ 1 (OR 12.9 [3.0-56.0]). Similarly, the odds ratio for any coronary artery disease varied with the 13 14 lowest increase observed for an EDACS score ≥ 16 (OR 2.7 [1.3-5.3]) and the highest increase for a TIMI risk score ≥ 1 (OR 8.8 [4.0-19.2]), respectively (*Figure 3*). 15 16 17 The positive predictive value (PPV) was low for all scores and the negative predictive value varied widely. Across all clinical risk scores, a GRACE 2.0 score of >88 had the highest 18 positive predictive value for obstructive coronary artery disease identifying 39% as high-risk 19 20 with a PPV of 41.9% (30.4-54.2% confidence interval). The negative predictive value (NPV) 21 varied from 77.3% to 95.2% but was highest for a TIMI score of 0 identifying 26% as low 22 risk with a NPV of 95.2% (87.2-100%) (Figure 4 & Supplemental Table 3). Similar findings 23 were observed when considering any coronary artery disease (Supplementary Table 4). 24

25 High sensitivity troponin I versus clinical risk scores

1	All clinical risk scores had a higher discriminatory performance than high-sensitivity cardiac
2	troponin alone (area under receiver operator curve [AUC] 0.481 [0.383-0.580 confidence
3	interval] and $0.533 [0.440 - 0.625]$ for any coronary artery disease and obstructive disease,
4	respectively). The TIMI risk score had the highest discrimination for coronary artery disease
5	and obstructive disease (0.784 [0.713 - 0.854] and 0.730 [0.653 - 0.808], respectively). The
6	lowest performing clinical risk score was EDACS for both coronary artery disease and
7	obstructive disease (0.684 [0.597 - 0.772] and 0.649 [0.555 - 0.743], respectively) (<i>Figure 5</i>).
8	
9	
10	Patients without previous diagnosis of coronary artery disease
11	In a sensitivity analysis restricted to the 103 (62%) patients not previously known to have
12	coronary artery disease, the discrimination for coronary artery disease and obstructive disease
13	of all risk scores was higher than cardiac troponin alone (cardiac troponin, $AUC = 0.472$
14	[0.383–0.580] and 0.584 [0.440–0.625], respectively). Discrimination was greatest for
15	SCORE2 for the outcome of any coronary artery disease (0.753 [0.659 - 0.846] and for the
16	PCE for the outcome of obstructive disease (0.747 [0.639 - 0.856]). EDACS again had the
17	lowest discrimination for coronary artery disease and obstructive disease (0.658 [0.551-
18	0.764] and 0.641 [0.488-0.795], respectively) (Supplemental Figure 3 and Supplemental
19	$T_{ablas} = \left(\begin{array}{c} \rho \\ \rho \end{array} \right)$

1 **Discussion**

In this study, we evaluated the performance of six established clinical risk scores to 2 3 determine whether they could help to identify patients with intermediate troponin levels who 4 are more likely to have coronary artery disease after myocardial infarction has been ruled out 5 in the Emergency Department. We found that all risk scores improve the odds of identifying 6 patients with coronary artery disease on CCTA. Using the existing risk threshold for each 7 score, the positive predictive value is low for all, with the best performing being the GRACE 8 2.0 score which correctly identified 4 in 10 patients with obstructive disease. The negative 9 predictive value was also low, with the best performing score being TIMI which correctly 10 identifies 19 of 20 patients as not having obstructive disease.

11

12 Patients with suspected acute coronary syndrome are at risk of future myocardial infarction 13 or cardiac death even after myocardial infarction has been ruled out therefore clinical 14 guidelines recommend further non-invasive investigations to identify potential underlying coronary artery disease [5, 14]. CCTA has been suggested as the non-invasive investigation 15 16 modality of choice due to its ability to accurately assess coronary artery plaque burden and 17 characteristics to guide use of secondary preventative therapies such as antiplatelets and 18 statins to modify their risk of future major adverse cardiovascular outcomes [2, 33-35]. 19 However, given resource constraints and the large volume of patients presenting with 20 suspected acute coronary syndrome, it would be valuable to develop strategies to select 21 patients with a higher pre-test probability of coronary artery disease to avoid unnecessary 22 CCTA. In our previous analysis, we demonstrated that high-sensitivity cardiac troponin I can 23 help identify patients with a higher prevalence of coronary artery disease for further testing 24 after myocardial infarction has been ruled out. Those with intermediate cardiac troponin 25 concentrations had 3-times higher odds of having coronary artery disease compared to those

with very low troponin concentrations. However, this remains a substantial group of patients,
comprising approximately 1 in 4 of all patients with suspected acute coronary syndrome in
whom cardiac troponin testing alone does not further discriminate those who are likely to
have coronary artery disease. Strategies to refine risk in this group of patients could therefore
help target further investigations more judiciously.

6

7 Multiple risk scores have been developed and validated for the initial triage of patients with 8 suspected acute coronary syndrome and for the risk stratification of apparently healthy 9 individuals [5, 17, 21, 25-31]. These risk scores are recommended by clinical guidelines to 10 guide early referral for specialist investigation such as invasive coronary angiography or 11 initiation of preventative medications [2, 14]. Given that these risk scores incorporate known 12 cardiovascular risk factors and were primarily developed to predict risk of major adverse cardiovascular outcomes, it is perhaps not surprising that they also improve the identification 13 14 of patients with coronary artery disease in the Emergency Department. Nevertheless, none of the risk scores we have evaluated had optimal rule-in and rule-out performance for any or 15 16 obstructive coronary artery disease and implementing multiple risk scores for this purpose 17 would be challenging in practice. Developing novel risk stratification tools specifically for 18 this group of patients could overcome this current limitation of existing risk scores.

19

We acknowledge there are limitations to our analysis. We did not have high-sensitivity
cardiac troponin T measurements for this cohort and so could not include an analysis of the
Troponin-only Manchester Acute Coronary Syndromes score [36]. The EDACS and TIMI
scores use a previous history of varying degrees of coronary artery disease as components of
the score, which may inflate their performance. However, in a sensitivity analysis restricted
to patients without previously known coronary artery disease, the negative predictive value

and positive predictive value for these scores remained similar. While the risk scores
evaluated here were designed to predict risk of short- or long-term clinical outcomes rather
than to diagnose coronary artery disease, this is the underlying pathophysiological basis of
the majority of adverse cardiovascular events, and the diagnosis of coronary artery disease is
important to patients with chest pain and can facilitate the targeting of preventative therapies
that could reduce risk of these outcomes.

7

8 Conclusions

9 In patients with intermediate cardiac troponin concentrations in whom myocardial infarction
10 has been ruled out, clinical risk scores can help identify patients with and without obstructive
11 coronary artery disease, but the performance of established risk thresholds requires
12 optimisation for this purpose.

1 Funding

Dr Williams is supported by the British Heart Foundation (FS/ICRF/20/26002). Dr Mills is
supported by a Chair Award (CH/F/21/90010), Programme Grant (RG/20/10/34966), and
Research Excellence Award (RE/18/5/34216) from the British Heart Foundation. Dr Lee is
supported by a British Heart Foundation Clinical Research Training Fellowship
(FS/18/25/33454).

7

8 Disclosures

9 Dr Williams has received speaker fees from Cannon Medical Systems, Siemens Healthineers
10 and Novartis. Dr Mills reports research grants awarded to the University of Edinburgh from
11 Abbott Diagnostics, Siemens Healthineers and Roche Diagnostics outside the submitted
12 work, and honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics,
13 LumiraDx and Psyros Diagnostics. All other authors have no interests to declare.
14

15 Acknowledgements

16 The authors gratefully acknowledge the BHF Cardiovascular Biomarker Laboratory,

17 University of Edinburgh, for their assistance with this work.

References: 2

~		
3	1.	Collet, J.P., et al., 2020 ESC Guidelines for the management of acute coronary
4		syndromes in patients presenting without persistent ST-segment elevation. Eur Heart
5 6	2.	Writing Committee, M., et al., 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR
7 8		Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical
9		Practice Guidelines. J Am Coll Cardiol, 2021. 78 (22): p. e187-e285.
10	3.	Shah, A.S.V., et al., High-sensitivity troponin in the evaluation of patients with
11 12		suspected acute coronary syndrome: a stepped-wedge, cluster-randomised
12 13	4	Body B et al Ranid exclusion of acute myocardial infarction in natients with
13 14	ч.	undetectable troponin using a high-sensitivity assay I Am Coll Cardiol 2011 58 (13):
15		p. 1332-9.
16	5.	Shah, A.S., et al., High-sensitivity cardiac troponin I at presentation in patients with
17 18		suspected acute coronary syndrome: a cohort study. Lancet, 2015. 386 (10012): p. 2481-8
19	6.	Chapman, A.R., et al., Comparison of the Efficacy and Safety of Early Rule-Out
20	0.	Pathways for Acute Myocardial Infarction. Circulation. 2017. 135 (17): p. 1586-1596.
21	7.	Anand, A., et al., <i>High-Sensitivity Cardiac Troponin on Presentation to Rule Out</i>
22		Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial.
23		Circulation, 2021. 143 (23): p. 2214-2224.
24	8.	Jaffe, A.S., et al., Single Troponin Measurement to Rule Out Myocardial Infarction:
25		JACC Review Topic of the Week. J Am Coll Cardiol, 2023. 82(1): p. 60-69.
26	9.	Allen, B.R., et al., Diagnostic Performance of High-Sensitivity Cardiac Troponin T
27		Strategies and Clinical Variables in a Multisite US Cohort. Circulation, 2021. 143(17):
28		p. 1659-1672.
29	10.	Chapman, A.R., et al., Association of High-Sensitivity Cardiac Troponin I
30 31		Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome, JAMA, 2017, 318 (19); p. 1913-1924.
32	11.	Bularga, A., et al., High-Sensitivity Troponin and the Application of Risk Stratification
33		Thresholds in Patients With Suspected Acute Coronary Syndrome. Circulation, 2019.
34		140 (19): p. 1557-1568.
35	12.	Cullen, L., et al., Validation of high-sensitivity troponin I in a 2-hour diagnostic
36		strategy to assess 30-day outcomes in emergency department patients with possible
37		acute coronary syndrome. J Am Coll Cardiol, 2013. 62(14): p. 1242-1249.
38	13.	Reichlin, T., et al., One-hour rule-out and rule-in of acute myocardial infarction using
39		high-sensitivity cardiac troponin T. Arch Intern Med, 2012. 172 (16): p. 1211-8.
40	14.	Byrne, R.A., et al., 2023 ESC Guidelines for the management of acute coronary
41		syndromes. Eur Heart J Acute Cardiovasc Care, 2023.
42	15.	Mahler, S.A., et al., The HEART Pathway randomized trial: identifying emergency
43		department patients with acute chest pain for early discharge. Circ Cardiovasc Qual
44		Outcomes, 2015. 8 (2): p. 195-203.
45	16.	Than, M.P., et al., Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic
46 47		Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within <i>Practice</i> . Annals of Emergency Medicine, 2016. 68 (1): p. 93-102.

1 2	17.	Than, M., et al., <i>Development and validation of the Emergency Department</i> Assessment of Chest pain Score and 2 h accelerated diagnostic protocol. Emergency
3		Medicine Australasia, 2014, 26 (1): p. 34-44.
4	18.	Flaws, D., et al., External validation of the emergency department assessment of
5		chest pain score accelerated diagnostic pathway (EDACS-ADP). Emergency Medicine
6		Journal. 2016. 33 (9): p. 618-625.
7	19.	Chapman, A.R., et al., High-Sensitivity Cardiac Troponin Land Clinical Risk Scores in
8		Patients With Suspected Acute Coronary Syndrome. Circulation, 2018, 138 (16): p.
9		1654-1665.
10	20.	Balasubramanian. R.N., et al., Role and relevance of risk stratification models in the
11	-	modern-day management of non-ST elevation acute coronary syndromes. Heart.
12		2023. 109 (7): p. 504-+.
13	21.	Lee, K.K., et al., Troponin-Guided Coronary Computed Tomographic Angiography
14		After Exclusion of Myocardial Infarction. J Am Coll Cardiol. 2021. 78 (14): p. 1407-
15		1417.
16	22.	Shah, A.S., et al., High sensitivity cardiac troponin and the under-diagnosis of
17		mvocardial infarction in women: prospective cohort study. BMJ. 2015. 350 : p. g7873.
18	23.	Diamond, G.A. and J.S. Forrester. <i>Analysis of Probability as an Aid in the Clinical</i> -
19		Diggnosis of Coronary-Artery Disease. New England Journal of Medicine, 1979.
20		300 (24): p. 1350-1358.
21	24.	Abbara, S., et al., SCCT guidelines for the performance and acquisition of coronary
22		computed tomographic angiography: A report of the society of Cardiovascular
23		Computed Tomography Guidelines Committee Endorsed by the North American
24		Society for Cardiovascular Imagina (NASCI). Journal of Cardiovascular Computed
25		Tomography, 2016, 10 (6); p. 435-449.
26	25.	Mahler, S.A., et al., The HEART Pathway Randomized Trial: Identifying Emergency
27		Department Patients with Acute Chest Pain for Early Discharge. Circulation. 2014.
28		130 .
29	26.	Elbarouni, B., et al., Validation of the Global Registry of Acute Coronary Event
30		(GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome
31		<i>in Canada</i> . American Heart Journal, 2009. 158 (3): p. 392-399.
32	27.	Scirica. B.M., et al., Validation of the thrombolysis in myocardial infarction (TIMI) risk
33		score for unstable anging pectoris and non-ST-elevation myocardial infarction in the
34		<i>TIMI III registry.</i> Am J Cardiol, 2002. 90 (3): p. 303-5.
35	28.	Goff, D.C., Jr., et al., 2013 ACC/AHA guideline on the assessment of cardiovascular
36		risk: a report of the American College of Cardiology/American Heart Association Task
37		Force on Practice Guidelines. J Am Coll Cardiol, 2014. 63(25 Pt B): p. 2935-2959.
38	29.	Rana, J.S., et al., Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a
39		Large Contemporary, Multiethnic Population. J Am Coll Cardiol, 2016. 67(18): p.
40		2118-2130.
41	30.	Hageman, S., et al., SCORE2 risk prediction algorithms: new models to estimate 10-
42		year risk of cardiovascular disease in Europe. European Heart Journal, 2021. 42(25):
43		p. 2439-2454.
44	31.	de Vries, T.I., et al., SCORE2-OP risk prediction algorithms: estimating incident
45		cardiovascular event risk in older persons in four geographical risk regions. European
46		Heart Journal, 2021. 42 (25): p. 2455-2467.

- Jakobsen, J.C., et al., When and how should multiple imputation be used for handling
 missing data in randomised clinical trials a practical guide with flowcharts. Bmc
 Medical Research Methodology, 2017. 17.
- Williams, M.C., et al., *Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study*. J Am Coll Cardiol, 2019. **73**(3): p. 291301.
- Andelius, L., et al., Impact of statin therapy on coronary plaque burden and
 composition assessed by coronary computed tomographic angiography: a systematic
 review and meta-analysis. Eur Heart J Cardiovasc Imaging, 2018. 19(8): p. 850-858.
- 35. Haase, R., et al., Diagnosis of obstructive coronary artery disease using computed
 tomography angiography in patients with stable chest pain depending on clinical
 probability and in clinically important subgroups: meta-analysis of individual patient
 data. BMJ, 2019. 365: p. 11945.
- Body, R., et al., *Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts.* Emerg Med J, 2017. **34**(6): p. 349-356.
- 17 18

	All participants (n = 167)	No coronary artery disease (n = 47)	Any coronary artery disease (n = 120)	P-value ¹
Female sex	46 (28%)	19 (40%)	27 (23%)	0.033
Age, years	64 (12)	56 (13)	67 (10)	< 0.001
Presenting symptom				
Chest pain	143 (86%)	37 (79%)	106 (88%)	0.14
Anginal symptoms	76 (46%)	21 (45%)	55 (46%)	0.99
Cardiovascular risk factor				
BMI, kg/m2	29.3 (5.8)	29.6 (5.2)	29.2 (6.0)	0.73
Current or previous smoker	89 (53%)	18 (38%)	71 (59%)	0.017
Hypertension	79 (47%)	11 (23%)	68 (57%)	< 0.001
Diabetes	30 (18%)	3 (6.4%)	27 (23%)	0.014
Hyperlipidaemia	33 (20%)	10 (22%)	23 (19%)	0.83
Family history	64 (38%)	17 (36%)	47 (39%)	0.86
Chronic kidney disease	19 (11%)	2 (4.3%)	17 (14%)	0.010
Medical history				
Angina	34 (20%)	2 (4.3%)	32 (27%)	0.001
Myocardial infarction	40 (24%)	3 (6.4%)	37 (31%)	< 0.001
Stroke	13 (7.8%)	2 (4.3%)	11 (9.2%)	0.36
Peripheral vascular disease	6 (3.6%)	0 (0%)	6 (5.0%)	0.19
Previous revascularization				
PCI	40 (24%)	3 (6.4%)	37 (31%)	< 0.001
CABG	10 (6.0%)	0 (0%)	10 (8.3%)	0.064
Physiology and investigations				
Ischemia on ECG	8 (4.8%)	3 (6.4%)	5 (4.2%)	0.69
T-wave inversion	24 (15%)	5 (11%)	19 (16%)	0.62
Heart rate, bmp	76 (18)	77 (20)	76 (18)	0.87
Systolic BP, mm Hg	151 (27)	152 (22)	151 (29)	0.90
Haemoglobin, g/L	143 (15)	143 (16)	143 (14)	0.95
Creatine	82 (19)	79 (19)	83 (19)	0.25
eGFR, mL/min/1.73 m2	82 (18)	87 (18)	80 (17)	0.022
Total cholesterol, mmol/L	4.82 (1.18)	5.18 (0.95)	4.67 (1.23)	0.005
LDL cholesterol, mmol/L	2.96 (1.18)	3.30 (0.94)	2.84 (1.24)	0.011
Peak cardiac troponin I, ng/L	8 (6, 12)	8 (7, 13)	8 (6, 12)	0.70
Clinical risk scores				
HEART	4 (3, 5)	3 (2, 4.5)	5 (4, 5)	< 0.001
EDACS	17 (12, 21)	14 (10.8, 17)	18(13, 21.3)	< 0.001
GRACE	78 (64, 96)	62 (45, 73)	86 (69, 102)	< 0.001
TIMI	1 (0, 2)	0 (0, 1)	2 (1, 2)	< 0.001

Table 1. Baseline characteristics of patients with intermediate cardiac troponin concentrations stratified by findings on coronary computed tomography angiography.

Table 1. Baseline characteristics of patients with intermediate cardiac troponin concentrations stratified by findings on coronary computed tomography angiography.

	All participants (n = 167)	No coronary artery disease (n = 47)	Any coronary artery disease (n = 120)	P-value ¹
PCE	0.19 (0.08, 0.36)	0.09 (0.04, 0.16)	0.26 (0.13, 0.38)	< 0.001
SCORE2/OP	10.5 (5, 16)	5 (4, 9)	12.5 (7, 18)	< 0.001

Values are median (interquartile range), n (%) or mean \pm SD. ¹ Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test. BMI = body mass index; BP = blood pressure; bmp = beats per minute; CABG = coronary artery bypass grafting; CAD = coronary artery disease; ECG = electrocardiogram; EDACS = Emergency Department Assessment of Chest Pain Score; eGFR = estimated glomerular filtration rate; GRACE 2.0 = Global Registry of Acute Coronary Events version 2.0; HEART = History, ECG, Age, Risk factors, Troponin; LDL = low-density lipoprotein; PCE = pooled cohort equations; PCI = percutaneous coronary intervention; SCORE2/OP = Systematic COronary Risk Evaluation 2/Older Population; TIMI = Thrombolysis In Myocardial Infarction.

1 Figure Legends

2

3 Figure 1. Distribution of risk scores in patients with suspected acute coronary syndrome 4 and intermediate cardiac troponin concentrations stratified using established risk score 5 thresholds as low-, moderate-, or high-risk. 6 * When EDACS and SCORE2/OP are applied further criteria are recommended (Supplement 7 Text 1) (8). 8 9 Figure 2. Proportion of patients with suspected acute coronary syndrome and 10 intermediate cardiac troponin concentrations found to have any coronary artery disease 11 (panel a) or obstructive disease (panel b) on CCTA below or above established low-risk thresholds for each risk score. 12 13 * When EDACS and SCORE2/OP are applied further criteria are recommended (Supplemental Text 1). CAD = coronary artery disease, CCTA = coronary computer 14 15 tomography angiography. 16 Figure 3. Odds ratio of having any or obstructive coronary artery disease on CCTA in 17 18 patients with suspected acute coronary syndrome and intermediate cardiac troponin 19 concentrations stratified by risk scores. 20 Odds ratios for any coronary artery disease and obstructive disease on CCTA in patients with 21 intermediate cardiac troponin concentrations comparing those with scores above and below 22 established risk thresholds. 23 24 Figure 4. Radar plot comparing diagnostic performance of risk scores for any coronary 25 artery disease (panel a) and obstructive disease (panel b) in patients with suspected acute coronary syndrome and intermediate cardiac troponin concentrations. 26

- AUC = area under the curve, NPV = negative predictive value, PPV = positive predictive
 value.

4	Figure 5. Discrimination of cardiac troponin and clinical risk scores for any coronary
5	artery disease (panel a) and obstructive disease (panel b) in patients with suspected
6	acute coronary syndrome and intermediate cardiac troponin concentrations.
7	Receiver-operating-characteristic curves illustrating discrimination of cardiac troponin and
8	clinical risk scores for coronary artery disease (panel a) and obstructive disease (panel b) in
9	patients with suspected acute coronary syndrome and intermediate cardiac troponin
10	concentrations.
11	









1	Figure 3.				
	Risk Scores (Threshold)	Below threshold Proportion with coronary artery disease (%)	Above threshold Proportion with coronary artery disease (%)		Odds Ratio (95% CI)
	Any coronary artery disease				
	HEART (<4)	20/47 (43)	100/120 (83)	⊢	6.7 (3.2-14.3)
	EDACS (<16)*	38/64 (59)	82/103 (80)	⊧ -	2.7 (1.3-5.3)
	GRACE 2.0 (≤88)	65/102 (64)	55/65 (85)	⊢−−− ■	3.1 (1.4-6.9)
	TIMI (=0)	16/43 (37)	104/124 (84)	▶ ─── ₩	8.8 (4.0-19.2)
	PCE (<5%)	6/18 (33)	114/149 (77)	⊢	6.5 (2.3-18.6)
	SCORE2/OP (<5%)*	12/23 (52)	108/144 (75)	⊢	2.7 (1.1-6.8)
	Obstructive coronary artery disease				
	HEART (<4)	3/47 (6)	47/120 (39)	F	9.4 (2.8-32.2)
	EDACS (<16)*	13/64 (20)	37/103 (36)	⊢−−− 4	2.2 (1.1-4.6)
	GRACE 2.0 (≤88)	23/102 (23)	27/65 (42)	⊢⊟ (2.4 (1.2-4.8)
	TIMI (=0)	2/43 (5)	48/124 (39)	\longmapsto	12.9 (3.0-56.0)
	PCE (<5%)	1/18 (6)	49/149 (33)	\longmapsto	8.3 (1.1-64.4)
	SCORE2/OP (<5%)*	3/23 (13)	47/144 (33)		3.2 (0.9-11.4)





